This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cesano, A. Articles by Santoli, D. Search for Related Content PubMed PubMed Citation Articles by Cesano, A. Articles by Santoli, D.

Antitumor Efficacy of a Human Major Histocompatibility Complex Nonrestricted Cytotoxic T-Cell Line (TALL-104) in Immunocompetent Mice Bearing Syngeneic Leukemia¹

The Wistar Institute, Philadelphia, Pennsylvania 19104

The human MHC nonrestricted cytotoxic T-cell line TALL-104 displays potent tumoricidal activity both in vitro and in animals bearing either spontaneous or induced tumors. In the present study, we used B6D2F1 mice engrafted with the syngeneic pre-B leukemia cell line 7OZ as a model system to investigate the mechanisms by which TALL-104 cells display antitumor activity in an immunocompetent host. In vitro studies indicated that 7OZ cells are resistant to TALL-104 cell-induced necrotic death, as measured in ⁵¹Cr release assays, but can be killed by the xenogeneic effectors via apoptotic mechanisms. Adoptive transfer experiments showed that 70% of cyclosporin A-treated mice that received multiple i.p. injections of -irradiated (nonproliferating) TALL-104 cells at an early or intermediate stage of disease did not develop any clinical or molecular signs of leukemia. If the same treatment was initiated at an advanced disease stage, it doubled the survival of the animals. Importantly, 100% of the treated mice that remained disease-free in a 4-month follow-up period rejected a further challenge of high-dose 7OZ cells; these mice had developed tumor-specific humoral and cellular responses. In another set of experiments, marrows from leukemic mice containing 10% 7OZ cells were purged ex vivo with irradiated TALL-104 cells and engrafted into sublethally irradiated B6D2F₁ mice; up to 80% of the recipients failed to develop leukemia, and 40% of them were protected against a 7OZ rechallenge 4 months later. TALL-104 purging efficacy was lower if the marrows were infiltrated by 30%. Ex vivo purging with a human lymphokine-activated killer cell preparation in the same conditions proved to be less effective. The overall data indicate the potent antileukemic effects of TALL-104 cells in vivo and provide evidence that xenogeneic effectors can induce tumor regression via a dual mechanism of direct tumoricidal activity and recruitment of endogenous antitumor immunity.

¹ This work was supported by grants from the American Cancer Society (DHP-107), the Maxfield Foundation, and the Mary L. Smith Charitable Lead Trust.

² To whom requests for reprints should be addressed, at The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104. Phone: (215) 898-3978; Fax: (215) 573-7919.

Received 5/23/96. Accepted 8/16/96.

This article has been cited by other articles:

				C. Brando, S. Mukhopadhyay, E. Kovacs, R. Medina, P. Patel, T. L. Catina, K. S. Campbell, and D. Santoli Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104 J. Leukoc. Biol., August 1, 2005; 78(2): 359 - 371. [Abstract] [Full Text] [PDF]

				G. G. Gomez, S. B. Read, L. E. Gerschenson, D. Santoli, A. Zweifach, and C. A. Kruse Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors Neuro-oncol, April 1, 2004; 6(2): 83 - 95. [Abstract] [PDF]

				R. Somasundaram, L. Jacob, R. Swoboda, L. Caputo, H. Song, S. Basak, D. Monos, D. Peritt, F. Marincola, D. Cai, et al. Inhibition of Cytolytic T Lymphocyte Proliferation by Autologous CD4+/CD25+ Regulatory T Cells in a Colorectal Carcinoma Patient Is Mediated by Transforming Growth Factor-{beta} Cancer Res., September 15, 2002; 62(18): 5267 - 5272. [Abstract] [Full Text] [PDF]

				C. A. Kruse, S. Visonneau, B. K. Kleinschmidt-DeMasters, C. J. Gup, G. G. Gomez, D. B. Paul, and D. Santoli The Human Leukemic T-Cell Line, TALL-104, Is Cytotoxic to Human Malignant Brain Tumors and Traffics through Brain Tissue: Implications for Local Adoptive Immunotherapy Cancer Res., October 1, 2000; 60(20): 5731 - 5739. [Abstract] [Full Text]

				S. Visonneau, A. Cesano, D. L. Porter, S. L. Luger, L. Schuchter, M. Kamoun, M. H. Torosian, K. Duffy, C. Sickles, E. A. Stadtmauer, et al. Phase I Trial of TALL-104 Cells in Patients with Refractory Metastatic Breast Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1744 - 1754. [Abstract] [Full Text]

				B. Geoerger, C.-B. Tang, A. Cesano, S. Visonneau, S. Marwaha, K. D. Judy, L. N. Sutton, D. Santoli, and P. C. Phillips Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts Neuro-oncol, April 1, 2000; 2(2): 103 - 113. [Abstract] [PDF]

				S. Visonneau, A. Cesano, K. A. Jeglum, and D. Santoli Adjuvant Treatment of Canine Osteosarcoma with the Human Cytotoxic T-Cell Line TALL-104 Clin. Cancer Res., July 1, 1999; 5(7): 1868 - 1875. [Abstract] [Full Text] [PDF]